Navigation Links
CEL-SCI Takes Delivery of New Manufacturing Facility
Date:10/9/2008

t will increase their survival. Head and neck cancer is one of the world's biggest cancers affecting about 650,000 people per annum worldwide.

About CEL-SCI's Phase III Cancer Drug Multikine:

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007. In the summer of 2007 CEL-SCI started construction of the manufacturing facility to produce Multikine for the Phase III trial and subsequent sale following approval.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit their effectiveness.

CEL-SCI has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense. Most recently CEL-SCI announced that its newly discovered rheumatoid arthritis vaccine showed excellent results in animal tests.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
6. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
7. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
8. Ground-Breaking Conference Takes on Abortion
9. White Paper Advises Pharma Manufacturers on How to Select an Aseptic Fill/Finish Contractor, Avoid the Most Common Mistakes
10. Ganeden Biotech Takes Sustenex(TM) National with GanedenBC30 Probiotic
11. Tepper School Team Takes Top Honors at Global Moot Corp(R) Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
(Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., a ... food processing industry, is asking industry professionals to prepare ... of the E2 soap they’re currently using to the ... . Hand hygiene is critical to fighting cross-contamination ... environment. Six key criteria are identified to evaluate the ...
(Date:8/28/2014)... August 28, 2014 “This kit has an ... screen from 0 to 150 ppb,” said Mark Tess, PhD, ... significant benefit to plant owners and USDA-GIPSA inspection agencies that ... commodities. Testing can take place in a matter of minutes ... the plant test the feed and grain before accepting it, ...
(Date:8/28/2014)... important devices in spintronics, an electronic which is ... but also on their spin and the spin-related ... into magnetic signals and vice versa. Recently, the ... Institute of Physics at Johannes Gutenberg University Mainz ... and Japan, has for the first time realised ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3
... , , , , , , Multiporator / Electroporator 2510 , , , ... , Transformation Protocol , Protocol No. 4308 915.525 ... , , , , , , ... , Cell type , ...
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.523 03/2002 , , , ... , Microorganism , Mycobacterium ... type , Bacteria, gram positive, , ...
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.512 04/2002 , ... , , , , ... , Cell type , Bacteria, ...
Cached Biology Technology:Nocardia asteroides 2Mycobacterium avium 2Escherichia coli DH5 2Escherichia coli DH5 3
(Date:8/28/2014)... peer groups and clinicians is critical to the ... University of Georgia research. , A qualitative study ... determined that role models for successful breastfeeding help ... , "Mothers who received that support are more ... co-author Alex Anderson, an associate professor in the ...
(Date:8/28/2014)... compounds that could positively impact the global ... possible, thanks to researchers in Penn State,s ... suppository made from the seaweed-derived food ingredient ... Tenofovir provides a woman-initiated, drug-delivery vehicle that ... transmitted infections during unprotected heterosexual intercourse, the ...
(Date:8/28/2014)... WASHINGTON, Aug. 28, 2014A new method for measuring and ... help doctors and researchers better understand how drug abuse ... surgery and tissue engineering, and lead to better treatment ... by a team of researchers from Stony Brook University ... of Health, was published today in The Optical Society,s ...
Breaking Biology News(10 mins):Breastfeeding study shows need for effective peer counseling programs 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3
... SANTA CRUZ, CA--The emerging field of "personalized" or ... cancer. If scientists can identify the genetic changes that ... information to develop targeted treatments. But achieving this goal ... and a sophisticated infrastructure to manage and analyze the ...
... stunning observation of the architecture within a cell ... changes during the formation of gametes, also known as ... process. The findings by the international team led ... treatment of disorders caused by a misregulation of cellular ...
... April 30, 2012 -- Autism has a strong genetic basis, ... had mixed results. The reason for this is that autism ... involved in different individuals, making it hard to find the ... the Hebrew University of Jerusalem has shown that despite this ...
Cached Biology News:UC Santa Cruz builds national data center for cancer genome research 2UC Santa Cruz builds national data center for cancer genome research 3UC Santa Cruz builds national data center for cancer genome research 4UC Santa Cruz builds national data center for cancer genome research 5Scientists make stunning inner space observations 2Scientists make stunning inner space observations 3Researchers at Hebrew University identify genetic systems disrupted in autistic brain 2
Rabbit polyclonal to ZA20D3 ( Abpromise for all tested applications). entrezGeneID: 54469 SwissProtID: Q6FIF0...
P8B1...
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Biology Products: